Who Paid My Doc
Rivacor 7 DR-T
Device Cardiology/Vascular Diseases
PDI 04035479156794
General payments
$2,055,250
Research payments
$2,112,191
Through program year 2025, $2,055,250 in general payments and $2,112,191 in research payments were reported against Rivacor 7 DR-T (Cardiology/Vascular Diseases).
No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.
By program year
9 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | General | $9,073 | 224 |
| 2025 | Research | $176,819 | 100 |
| 2024 | General | $162,316 | 269 |
| 2024 | Research | $438,913 | 1,712 |
| 2023 | General | $268,247 | 489 |
| 2023 | Research | $742,115 | 3,788 |
| 2022 | General | $1,615,614 | 3,256 |
| 2022 | Research | $745,645 | 5,479 |
| 2021 | Research | $8,698 | 4 |
Breakdown
The top 5 of the 100 largest recipients; each share is of general payments naming this product in 2025.
The top 5 of 15 specialties; each share is of general payments naming this product to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.
The top 5 of 27 states; each share is of general payments naming this product in 2025 where a state was reported.
Records
4,238 general · 11,083 researchEvery payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
What you are looking at
Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.